tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2014 May 14. pii: CVI.00615-13. [Epub ahead of print]
Comparison of the Immunogenicity and Safety of Conventional Subunit, MF59-Adjuvanted, and Intradermal Influenza Vaccine in the Elderly.
Seo YB1, Choi WS1, Lee J2, Song JY1, Cheong HJ3, Kim WJ4.
Author information
Abstract
The influenza vaccination is known as the most effective method for preventing influenza and its complications in the elderly. Conventional subunit (Agrippal S1, Novartis), MF59-adjuvanted (Fluad, Novartis), and intradermal influenza vaccine (IDflu15, Sanofi Pasteur) are widely used throughout Korea. However, few comparative studies evaluating the safety and immunogenicity of these vaccines are available. Prior to the beginning of the 2011-2012 influenza season, 335 elderly healthy volunteers randomly received one of the three seasonal trivalent influenza vaccines: Conventional subunit, MF59-adjuvanted and intradermal influenza vaccine. Serum hemagglutination-inhibiting antibodies were measured at the time of vaccination and 1 month and 6 months after vaccination. Adverse events were recorded prospectively. A total of 113 conventional subunit, 111 MF59-adjuvanted, and 111 intradermal influenza vaccine volunteers were followed up during a 6-month post-vaccination period. One month after vaccination, all three vaccines satisfied CHMP criteria for A/H1N1 and A/H3N2 strains, but not the B strain. Compared with the subunit vaccine, the intradermal vaccine exhibited non-inferiority, while the MF59-adjuvanted vaccine exhibited superiority. Furthermore, the MF59-adjuvanted vaccine was more immunogenic towards the A/H3N2 strain than the subunit vaccine up to six months post-vaccination. The most common local and systemic reactions were local pain at the injection site and generalized myalgia. (7.1% vs. 10.8% vs. 6.3%; 0.9% vs. 8.1% vs. 5.4%, respectively) Local and systemic reactions were similar among the three vaccine groups. MF59-adjuvanted vaccine exhibited superior immunogenicity compared with a conventional subunit vaccine and had a comparable safety profile. For older adults, MF59-adjuvatned vaccine is preferable for providing superior immunogenicity.
Copyright ? 2014, American Society for Microbiology. All Rights Reserved.
PMID:
24828092
[PubMed - as supplied by publisher]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/24828092
Comparison of the Immunogenicity and Safety of Conventional Subunit, MF59-Adjuvanted, and Intradermal Influenza Vaccine in the Elderly.
Seo YB1, Choi WS1, Lee J2, Song JY1, Cheong HJ3, Kim WJ4.
Author information
Abstract
The influenza vaccination is known as the most effective method for preventing influenza and its complications in the elderly. Conventional subunit (Agrippal S1, Novartis), MF59-adjuvanted (Fluad, Novartis), and intradermal influenza vaccine (IDflu15, Sanofi Pasteur) are widely used throughout Korea. However, few comparative studies evaluating the safety and immunogenicity of these vaccines are available. Prior to the beginning of the 2011-2012 influenza season, 335 elderly healthy volunteers randomly received one of the three seasonal trivalent influenza vaccines: Conventional subunit, MF59-adjuvanted and intradermal influenza vaccine. Serum hemagglutination-inhibiting antibodies were measured at the time of vaccination and 1 month and 6 months after vaccination. Adverse events were recorded prospectively. A total of 113 conventional subunit, 111 MF59-adjuvanted, and 111 intradermal influenza vaccine volunteers were followed up during a 6-month post-vaccination period. One month after vaccination, all three vaccines satisfied CHMP criteria for A/H1N1 and A/H3N2 strains, but not the B strain. Compared with the subunit vaccine, the intradermal vaccine exhibited non-inferiority, while the MF59-adjuvanted vaccine exhibited superiority. Furthermore, the MF59-adjuvanted vaccine was more immunogenic towards the A/H3N2 strain than the subunit vaccine up to six months post-vaccination. The most common local and systemic reactions were local pain at the injection site and generalized myalgia. (7.1% vs. 10.8% vs. 6.3%; 0.9% vs. 8.1% vs. 5.4%, respectively) Local and systemic reactions were similar among the three vaccine groups. MF59-adjuvanted vaccine exhibited superior immunogenicity compared with a conventional subunit vaccine and had a comparable safety profile. For older adults, MF59-adjuvatned vaccine is preferable for providing superior immunogenicity.
Copyright ? 2014, American Society for Microbiology. All Rights Reserved.
PMID:
24828092
[PubMed - as supplied by publisher]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/24828092